Jemma Arakelyan, Chief Executive Officer at The Institute of Cancer and Crisis (ICC) and Medical Advisor at Immune Oncology Research Institute, shared a post on LinkedIn:
“Our new research is now published in the Journal of Medicinal Chemistry.
Platinum chemotherapeutics are effective but cause severe toxicity to healthy cells. To address this, we developed novel Pt(IV) prodrugs based on cisplatin, oxaliplatin, and carboplatin, featuring sunitinib-derived axial ligands for selective targeting of renal cell carcinoma.
These are the first Pt(IV) complexes designed to target renal tumors overexpressing VEGFR/PDGFR. The lead cisplatin-based prodrug showed:
- Superior in vitro & 3D spheroid activity over cisplatin
- High in vivo efficacy in renal carcinoma xenografts
- Enhanced tumor reduction with lower systemic toxicity
This work was an international collaboration with Maynooth University Chemistrydepartment and The Babak Lab at City University of Hong Kong.”
Title: Pt(IV) Prodrugs Bearing Sunitinib-Derived Ligands Display Exceptional Anticancer Activity against Renal Cell Carcinoma When Compared to Conventional Platinum Chemotherapy
Authors: Benjamin R. Roman, Allison Lipitz-Snyderman, Susan Chimonas, Brendan Raftery, Cole Manship, Arushi Mahajan, Leonard Saltz, Aaron Mitchell, David Miller, Smita Sihag, Daniel Gomez, Bobby Daly, Lauren Klein Levine
Read the Full Article.
More posts featuring Jemma Arakelyan.